¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Intraocular melanoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • superficial spreading melanoma
    ¾èÀºÈ®»ê¾Ç¼ºÈæ»öÁ¾
  • verrucous melanoma
    »ç¸¶±Í¾Ç¼ºÈæ»öÁ¾
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intraocular tension
    ¾È¾Ð
  • iridocapsular intraocular lens
    ȫä¼öÁ¤Ã¼³¶°íÁ¤·»Áî
  • iris-supported intraocular lens
    ȫäÁöÁö·»Áî
  • posterior chamber intraocular lens
    ÈĹ添Áî
  • toric intraocular lens
    ³­½ÃÀΰø¼öÁ¤Ã¼, Å丯Àΰø¼öÁ¤Ã¼
  • acral lentiginous melanoma in situ
    ¿øÀ§Ä¡ ¸»´Ü ÈæÀÚ¼ºÈæ»öÁ¾
  • balloon cell melanoma
    dz¼±¼¼Æ÷(ù¦àÏá¬øà)Èæ»öÁ¾(ýÙßäðþ)
  • benign juvenile melanoma
    ¾ç¼º ¿¬¼Ò¼º(åÐàõ æÄá´àõ)Èæ»öÁ¾(ýÙßäðþ)
  • choroidal melanoma
    ¸Æ¶ô¸·Èæ»öÁ¾
  • desmoplastic melanoma
    °áÇÕÁ¶Á÷ Çü¼º(Ì¿ùêðÚòÄ û¡à÷)Èæ»öÁ¾(ýÙßäðþ)
  • heritable melanoma syndrome
    À¯Àü¼ºÈæ»öÁ¾ÁõÈıº
  • juvenile melanoma
    ¿¬¼Ò¼º Èæ»öÁ¾(¡­ýÙßäðþ)
  • juvenile melanoma
    ¿¬¼Ò¼º Èæ»öÁ¾(¡­ýÙßäðþ).
  • lentigo maligna melanoma
    ¾Ç¼ºÈæÀÚ Èæ»öÁõ
  • lentigo maligna melanoma
    ¾Ç¼ºÈæÁ¡ÀÚÈæ»öÁ¾(äÂàõýÙïÇí­ýÙßäðþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IOP improving organizational performance; intraocular pressure
ITR intraocular tension recorder; intratracheal
T + 1, T + 2, T + 3 first, second, and third stages of increased intraocular tension
T-1, T-2, T-3 first, second, and third stages of decreased intraocular tension
Tn normal intraocular tension; transposon
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IOFB intraocular foreign body
ALM Acral lentiginous melanoma
A-Mel-3 Amelanotic melanoma
B16a B16 amelanotic melanoma
COMS Collaborative Ocular Melanoma Study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
    1. ¿ÜÀ½¿¡ »ý±â´Â °¡Àå Áß¿äÇÑ º´º¯ÀÎ Á¾¾çÀÇ ÀÏÁ¾À¸·Î ¿ÜÀ½ÀÇ ¾Ç¼º Èæ»öÁ¾Àº µå¹°°í, ¿©¼º¿¡¼­ °üÂûµÇ´Â Èæ»öÁ¾ÀÇ 2%°¡ ¿ÜÀ½¿¡¼­ ¹ß»ýÇÑ´Ù. 2. »ö¼Ò ¼¼Æ÷¿¡ »ý±ä ¾Ç¼º Á¾¾ç. 3. Ç¥ÇǼº Èæ»ö±¸¿Í ±× Àü±¸Ã¼·ÎºÎÅÍ ¹ß»ýÇÏ´Â ´ë´ÜÈ÷ ¾Ç¼ºÀÎ Á¾¾çÀÌ´Ù. ¸ðµç ¾Ç¼º Á¾¾ç Áß 1%°¡ ¾Ç¼º Èæ»öÁ¾ÀÌ´Ù. ÀÌÁß 90%´Â ¿ÜÇÇ¿¡ ³ªÅ¸³ª°í 10%´Â ÇǺΠ¿Ü¿¡ ³ªÅ¸³­´Ù. ¸ðµç ¾Ç¼º Èæ»öÁ¾ Áß 1%´Â ±¸°­ ³»¿¡¼­ ¹ß»ýÇÑ´Ù. ¹ß»ýÀ²ÀÌ Áõ°¡µÇ´Â °Íó·³ º¸ÀÌ´Â ÀÌ·± Á¾¾çÀÇ Æ¯È÷ ³ª»Û Á¡Àº ¸²ÇÁ ¼øÈ¯°ú Ç÷¾× ¼øÈ¯À» ÅëÇØ ºü¸£°Ô ÀüÀ̵Ǵ °ÍÀÌ´Ù.
  • malignany melanoma
    ¾Ç¼º Èæ»öÁ¾
  • melanoma
    Èæ»öÁ¾
    1. ÇǺγª ´Ù¸¥ ±â°üÀÇ melanocytic system¿¡¼­ »ý±ä Á¾¾ç. ÀÌ ¿ë¾î°¡ ´Üµ¶À¸·Î »ç¿ëµÉ ¶§´Â ¾Ç¼º Èæ»öÁ¾À» ÀÏÄ´´Ù. 2. ÇǺÎÀÇ ¾Ç¼º, ¾îµÎ¿î Âø»ö Á¡ ¶Ç´Â Á¾¾ç. ÇÇºÎ Èæ»öÁ¾ÀÇ 4°¡Áö Á¾·ù´Â Ç¥Àç È®»ê¼º Èæ»öÁ¾, ¾Ç¼º Èæ»öÁ¾, ¸»´Ü Èæ»öÁ¾, °áÀý¼º Èæ»öÁ¾ÀÌ´Ù. À̵é Áß Ã³À½ 3°¡Áö´Â Ç¥À缺À¸·Î ¼ºÀåÇÏ¸ç ¹æ»ç»óÀ¸·Î È®ÀåÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç ±íÀÌ Ä§ÅõÇÏÁö´Â ¾Ê´Â´Ù. °áÀý¼º Èæ»öÁ¾Àº ±íÀÌ Ä§ÅõÇϸç ÀüÀ̵ȴÙ. ¾Ç¼º Èæ»öÁ¾Àº 1995³â ¹Ì±¹¿¡¼­ 7,200¸íÀÇ »ç¸Á ¿øÀÎÀ̾ú´Ù.
  • melanoma in situ
    »óÇdz» Èæ»öÁ¾
  • superficially spreading melanoma
    ÆÛÁ®³ª°¡´Â Ç¥À缺 Èæ»öÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
cancer, malignant melanoma A skin cancer that begins in cells called melanocytes that can grow together to form benign (not cancerous) moles. A change in size, shape, or colour of a mole can be a sign of melanoma. Melanoma can be cured if detected early, before spread (metastasis) to other areas of the body. Diagnosis is confirmed with a biopsy of the abnormal skin. Sun exposure can cause skin damage that can lead to melanoma.
(12 Dec 1998)
cancer, melanoma A skin cancer that begins in cells called melanocytes that can grow together to form benign (not cancerous) moles. A change in size, shape, or colour of a mole can be a sign of melanoma. It can be cured if detected early, before spread (metastasis) to other areas. Diagnosis is confirmed by a biopsy of the abnormal skin. Sun exposure can cause skin damage that can lead to melanoma.
(12 Dec 1998)
malignant lentigo melanoma <tumour> A melanoma arising from a malignant lentigo.
(05 Mar 2000)
malignant melanoma <oncology, tumour> A malignant tumour which arises from the pigment producing cells (melanosomes) of the deeper layers of the skin (or the eye). Melanoma is the leading cause of death attributable to skin lesions. Described as an irregular dark skin lesion that may have areas of varying colour. Often greater than 6 mm in diameter.
(27 Sep 1997)
malignant melanoma: gallium imaging <radiology> Greater than50% sensitivity for primary and metastatic sites: 73% sensitivity if lesion is greater than 2 cm, 17% sensitivity if less than 2 cm, see: gallium: indications malignant melanoma
(12 Dec 1998)
malignant melanoma in situ A melanoma limited to the epidermis and composed of nests of atypical melanocytes and scattered single cells extending into the upper epidermis; local excision is curative although the lesion, if untreated, may soon invade the dermis. Malignant lentigo may be considered a slowly progressive type of malignant melanoma in situ.
(05 Mar 2000)
malignant melanoma: staging <radiology> Clark staging: level I: all tumour cells above basement membrane (in situ), level II: tumour extends to papillary dermis, level III: tumour extends to interface between papillary and reticular dermis, level IV: tumour extends between bundles of collagen of reticular dermis, level V: tumour invasion of sucutaneous tissue (87% metastases) Breslow staging: thin: less than 0.75 mm depth of invasion, intermediate: 0.76 - 3.99 mm depth of invasion, thick: greater than 4 mm depth of invasion see: malignant melanoma
(12 Dec 1998)
melanoma <oncology, tumour> A tumour arising from the melanocytic system of the skin and other organs. When used alone the term refers to malignant melanoma.
(18 Nov 1997)
melanoma, amelanotic An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin.
(12 Dec 1998)
melanoma growth stimulatory activity Cytokine of the C X C subfamily. Potent mitogen. Activates and is chemotactic for, neutrophils.
(18 Nov 1997)
minimal deviation melanoma <dermatology, tumour> A malignant melanoma showing less cytologic atypia than is usual in melanoma cells showing asymmetric expansile invasion of the dermis.
(05 Mar 2000)
Cloudman melanoma <tumour> A transplantable melanoma that arose spontaneously in a mouse of DBA strain, and which grows and metastasizes in mice of related strains.
(05 Mar 2000)
halo melanoma <tumour> A rare condition in which a melanoma is surrounded by an irregular area of depigmentation.
(05 Mar 2000)
Harding-Passey melanoma <tumour> A melanin-forming tumour that arose spontaneously in a non-inbred mouse, and that is transplantable to mice of many strains but does not ordinarily metastasize.
(05 Mar 2000)
Xiphophorus melanoma receptor kinase <enzyme> Growth factor receptor protein with an extracellular ligand binding domain and an intracellular catalytic domain
Registry number: EC 2.7.1.-
Synonym: xmrk protein
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á